Atlas Trials

A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma

Clinical trial NCT07150377 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07150377
Sponsor
The Second Affiliated Hospital of Shandong First Medical University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma (HCC)
Start date
2025-08-24
Primary completion
2026-08-24
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.